文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

经外周静脉导管输注血管活性药物的并发症:系统评价与荟萃分析

Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis.
PubMed 文献 · Am J Emerg Med · 2020-09-28
一句话结论经外周静脉导管输注血管活性药物的并发症总体患病率低(汇总0.086,95%CI 0.031-0.21),报告安全指南的研究并发症患病率更低(0.029 vs 0.12,p=0.024)。

该系统评价与荟萃分析检索PubMed、EMBASE和Scopus数据库至2020年2月2日,纳入9项研究、1835例患者(平均年龄63岁,标准差12,48%为女性),评估经外周静脉导管输注血管活性药物的并发症。共发生122例(7%)并发症,其中117例(96%)为轻微并发症。随机效应荟萃分析显示并发症汇总患病率为0.086(95%CI 0.031-0.21);报告输注安全指南的研究并发症患病率(0.029,95%CI 0.018-0.045)显著低于未报告安全指南的研究(0.12,95%CI 0.038-0.30,p=0.024)。作者认为经外周静脉导管输注血管活性药物的并发症患病率低,报告安全指南与更低的并发症患病率相关,需进一步研究确认。

要点

  • 纳入9项研究、1835例患者,经外周静脉导管输注血管活性药物的并发症汇总患病率为0.086(95%CI 0.031-0.21)。
  • 122例(7%)并发症中117例(96%)为轻微并发症。
  • 报告输注安全指南的研究并发症患病率为0.029(95%CI 0.018-0.045),未报告安全指南的研究为0.12(95%CI 0.038-0.30),差异有统计学意义(p=0.024)。
  • 作者认为经外周静脉导管输注血管活性药物的并发症患病率低,报告安全指南与更低的并发症患病率相关。
  • 作者指出需进一步研究确认上述观察结果。

适用人群与场景

  • 需要输注血管活性药物的休克患者,来自纳入的随机对照试验、队列研究和病例对照研究,排除病例报告。

研究设计与关键结果

  • 研究类型为随机效应荟萃分析,检索PubMed、EMBASE和Scopus数据库至2020年2月2日,纳入9项研究。
  • 共纳入1835例患者,平均年龄63岁(标准差12),48%为女性。
  • 共发生122例(7%)并发症,其中117例(96%)为轻微并发症。
  • 随机效应荟萃分析显示经外周静脉导管输注血管活性药物的并发症汇总患病率为0.086(95%CI 0.031-0.21)。
  • 报告输注安全指南的研究并发症患病率为0.029(95%CI 0.018-0.045),未报告安全指南的研究为0.12(95%CI 0.038-0.30),差异有统计学意义(p=0.024)。

证据类型、等级与局限

  • 证据类型为系统评价与荟萃分析,纳入随机对照试验、队列研究和病例对照研究,排除病例报告;使用Newcastle-Ottawa量表和Cochrane偏倚风险工具评估研究质量,采用Kappa评分评估评价者间一致性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为经外周静脉导管输注血管活性药物的并发症患病率低,报告输注安全指南与更低的并发症患病率相关。
  • 作者指出需进一步研究确认上述观察结果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Vasopressors are mainstay treatment for patients in shock and are usually infused through central venous catheters (CVCs). However, CVCs are associated with risk of infection or delay from the needs of confirmation of placement. Infusing vasopressor through peripheral venous catheter (PIVs) could be an alternative in the Emergency Departments (ED) but data regarding complications is inconclusive. We performed a random-effects meta-analysis to assess literature involving prevalence of complications from infusing vasopressors via PIVs.

METHODS: We searched PubMed, EMBASE and Scopus databases from beginnings to 02/02/2020 to identify relevant randomized control trials, cohort, case-control studies. We excluded case reports. Authors assessed studies' quality with Newcastle-Ottawa Scale and Cochrane Risk of Bias tool. Kappa score was used to assess interrater agreement. Outcome was complications as direct results from infusing vasopressors through PIVs.

RESULTS: We identified 325 articles and included 9 studies after reviewing 16 full text articles. Our analysis included 1835 patients whose mean age was 63 (Standard Deviation 12) years and 48% was female. There were 122 (7%) complications, of which 117 (96%) were minor. The meta-analysis with random effects showed the pooled prevalence of complications as 0.086 (95%CI 0.031-0.21). Studies reporting infusion safety guidelines had significantly lower prevalence of complications (0.029, 95%CI 0.018-0.045), compared to those not reporting a safety guideline (0.12, 95%CI 0.038-0.30, p = 0.024).

CONCLUSION: There was low prevalence of complications as a direct result from infusing vasopressors through PIVs. Studies with safety guidelines were associated with significantly lower prevalence of complications. Further studies are needed to confirm our observations.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Tran QK, Mester G, Bzhilyanskaya V, et al. Complication of vasopressor infusion through peripheral venous catheter: A systematic review and meta-analysis. Am J Emerg Med. 2020. PMID: 33039229. doi:10.1016/j.ajem.2020.09.047

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。